<DOC>
	<DOCNO>NCT02839941</DOCNO>
	<brief_summary>The objective study evaluate effect iguratimod concomitant conventional immunosuppressive drug prevent antibody-induced rejection HLA Highly mismatch Kidney Transplant recipient .</brief_summary>
	<brief_title>Iguratimod Kidney Transplant Recepients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Male female , age ≥18 , &lt; 65 year At least 2 week post kidney transplantation decease live donor Stable renal graft function , i.e. , serum creatinine undulation 3 consecutive test &lt; ±10 % Serum creatinine &lt; 1.5×upper limit normal ( ULN ) Number HLA mismatch ≥ 4 Panel Reactive Antibody ( PRA ) value pretransplantation &lt; 10 % Concentration conventional immunosuppressive drug reach target range Subjects willing participate study , fully inform , sign inform consent form ( ICF ) Women childbearing potential ( WOCBP ) must negative pregnancy test within 24 hour prior start study medication , agree use acceptable method avoid pregnancy entire study period 3 month last dose study medication . Pregnant nursing woman Currently clinical acute rejection ; Graft function n't recover delay graft function ( DGF ) , primary nonfunction ( PNF ) Second subsequent kidney transplant multiorgan recipient ( e.g . kidney pancreas ) Subjects Liver failure Abnormal hepatic , renal hematopoietic function , 1 . Alanine transaminase ( ALT ) , Aspartate transaminase ( AST ) &gt; 1.5×ULN 2 . White blood cell ( WBC ) &lt; 3.5×10^9/L 3 . Hemoglobin ( HGB ) &lt; 80 g/L 4 . Platelet count ( PLT ) &lt; 80×10^9/L . Severe clinically relevant disease , 1 . Abnormality chest X ray image , Tuberculosis , Pulmonary interstitial fibrosis , symptom physical sign clinical significance 2 . Serious cardiovascular , hepatic , hematological , endocrinal disease , malignancy 3）History serious cardiovascular , hepatic , hematological , endocrinal disease , malignancy 4 ) Immunodeficiency , uncontrolled active infection , active gastrointestinal disease . Women men childbearing potential plan pregnant recently ; Allergic study drug , excipient Subject psychiatric illness , may put him/her unacceptable risk opinion investigator Has receive receive Rituximab treatment Iguratimod treatment within 1 week pretransplantation , screen period Received live vaccine previous 3 month , plan receive live vaccine study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>